ライフサイエンスコーパス: pharmacokinetic

1 similar molecular weight and albumin driven pharmacokinetics.

2 ibution of GSK1265744 LAP and its associated pharmacokinetics.

3 proportional, with no effect on capecitabine pharmacokinetics.

4 olecular components controlling asparaginase pharmacokinetics.

5 ke mechanisms, biodistribution patterns, and pharmacokinetics.

6 points were DSM265 safety, tolerability, and pharmacokinetics.

7 there is large inter-patient variability in pharmacokinetics.

8 tant window into the study of physiology and pharmacokinetics.

9 a library of nanoparticles on their in vivo pharmacokinetics.

10 e (18)F-FLT biodistribution and to determine pharmacokinetics.

11 thy older people (n = 20, 65-79 years); (ii) pharmacokinetic, 18F-fallypride D2/3 receptor imaging an

12 However, none of the pharmacokinetic agents has demonstrated convincing precl

13 Pharmacokinetic analysis (n=86) showed a dose-proportion

14 In summary, the pharmacokinetic analysis along with the efficacy data em

15 Pharmacokinetic analysis demonstrated higher early renal

16 The population for the pharmacokinetic analysis included a subset of patients w

17 n the current study, we investigated several pharmacokinetic analysis methods to quantify changes in

18 The PNA method enables pharmacokinetic analysis of RNAi triggers, elucidates po

19 ly used in preclinical drug research for the pharmacokinetic analysis of therapeutic compounds in liv

20 In vivo pharmacokinetic analysis shows that GEBR-32a is rapidly

21 Response rate and pharmacokinetic analysis were secondary end points.

22 therapy (RRT)) were subjected to population pharmacokinetic analysis.

23 TRAIL-Fc, but also manifests more favorable pharmacokinetic and antitumor pharmacodynamic profiles i

24 Scrupulous comparison of the pharmacokinetic and clinical characteristics of generic

25 t the results of 2 studies investigating the pharmacokinetic and clinical outcomes of a new DCB to tr

26 t aims to identify radiotracers with optimal pharmacokinetic and dosimetric properties.

27 the first computational strategy to explore pharmacokinetic and drug interaction effects in evolutio

28 eived need for a Gd-free contrast agent with pharmacokinetic and imaging properties comparable to GBC

29 ined on a small-animal scanner to assess the pharmacokinetic and in vivo binding properties of the li

30 is needed to assess the differences in their pharmacokinetic and pharmacodymanic profiles.

31 The study objectives were to assess the pharmacokinetic and pharmacodynamic characteristics and

32 ding bedaquiline, delamanid, and linezolid), pharmacokinetic and pharmacodynamic considerations, prev

33 r next generation endoperoxide with combined pharmacokinetic and pharmacodynamic features that overco

34 end points were safety, side-effect profile, pharmacokinetic and pharmacodynamic measures, and change

35 cted for the expansion phase on the basis of pharmacokinetic and pharmacodynamic profiles and demonst

36 y assessed the maximum tolerated dose (MTD), pharmacokinetic and pharmacodynamic profiles, safety, an

37 ues for modulating Fe(II) reactivity and the pharmacokinetic and pharmacodynamic properties of 1,2,4-

38 represent a fundamental tool to evaluate the pharmacokinetic and pharmacodynamic properties of select

39 ted oligonucleotides has highlighted unusual pharmacokinetic and pharmacodynamic properties of these

40 The present method will enable pharmacokinetic and pharmacodynamic studies of p-XSC in

41 In an additional 138 patients enrolled in a pharmacokinetic and pharmacodynamic substudy from 4 phas

42 ercise capacity; (2) the population-specific pharmacokinetic and safety profile of KNO3 in heart fail

43 with higher aqueous solubility and enhanced pharmacokinetic and therapeutic properties.

44 -DFO-(89)Zr was stable in vivo and exhibited pharmacokinetic and tumor-targeting properties similar t

45 tabolic processing of STO-609, its toxicity, pharmacokinetics and bioavailability in a variety of mou

46 While dose dependencies in pharmacokinetics and clearance are often observed in cli

47 Here we report that the pharmacokinetics and clearance of renal clearable gold n

48 ovascular diseases are limited by short-term pharmacokinetics and extra-cardiac adverse effects.

49 intravenous (IV) infusion and to assess the pharmacokinetics and in vitro immunologic activity of th

50 harmacokinetics, spatial and temporal tissue pharmacokinetics and in vitro pharmacodynamics of these

51 The pharmacokinetics and metabolic stability of the probes w

52 formation and function, FQ plasma and tissue pharmacokinetics and pharmacodynamics and is based on ex

53 lerance, multiple comorbidities, and altered pharmacokinetics and pharmacodynamics.

54 ein therapeutics and for understanding their pharmacokinetics and pharmacodynamics.

55 Here, we evaluate the long-term pharmacokinetics and therapeutic efficacy of polycaprola

56 this study, we used PET imaging to study the pharmacokinetics and tumor delivery of a panel of anti-E

57 amolecular platforms that improved porphyrin pharmacokinetics and tumour-homing.

58 On the basis of safety, pharmacokinetic, and pharmacodynamic profiling, the RP2D

59 zebrafish assay and superior physiochemical, pharmacokinetic, and toxicologic properties, as well as

60 aim of this study was to assess the safety, pharmacokinetics, and activity of venetoclax in combinat

61 y was to assess the safety and tolerability, pharmacokinetics, and antiviral effect of a single dose

62 PR scaffolds exhibit absorption, pharmacokinetics, and biodistribution patterns that are

63 ts toxicities, maximum tolerated dose (MTD), pharmacokinetics, and clinical activity.

64 imaging to evaluate the safety, feasibility, pharmacokinetics, and dosimetry of (18)F-MFBG in neuroen

65 n study of oral leniolisib to assess safety, pharmacokinetics, and effects on lymphoproliferation and

66 We aimed to assess the safety, tolerability, pharmacokinetics, and efficacy of AZD3759 in patients wi

67 with NHL was conducted to determine safety, pharmacokinetics, and efficacy of venetoclax, a selectiv

68 cal proof of concept, specific tumor uptake, pharmacokinetics, and feasibility for intraoperative flu

69 e dose (MTCD) and evaluate safety, activity, pharmacokinetics, and immunogenicity of moxetumomab pasu

70 End points were safety, response, pharmacokinetics, and immunogenicity.

71 However, little is known about its pharmacokinetics, and mechanisms of therapy resistance a

72 compare the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of GP2013 plus cy

73 e compartment model can describe doxorubicin pharmacokinetics, and pharmacokinetic parameters vary si

74 This phase 1 study evaluated the safety, pharmacokinetics, and preliminary activity of vadastuxim

75 PET/CT-based biodistribution, pharmacokinetics, and radiation dosimetry were performed

76 e design, discovery, pharmacologic activity, pharmacokinetics, and safety of a CD3 T cell-dependent b

77 of 71 (79) displayed more optimal efficacy, pharmacokinetics, and safety, leading to its selection a

78 Materials and Methods Biodistribution, pharmacokinetics, and stability of CM-101 in rats were m

79 ort expansions to provide additional safety, pharmacokinetics, and target occupancy data.

80 This study utilised a population-based pharmacokinetic approach to optimise the antimalarial tr

81 s system have led to exploring protein-based pharmacokinetic approaches using biologics like vaccines

82 al challenges centered on chemistry, such as pharmacokinetics, are reduced.

83 y, and pilot in vivo data revealed favorable pharmacokinetics as well as engagement on both targets i

84 tumors, independent of formulation and other pharmacokinetic aspects, our results suggest that the ev

85 Secondary objectives included pharmacokinetic assessment and open-label evaluation of

86 Pharmacokinetic assessment of ibrutinib exposure at 420-

87 amotrigine products and completed at least 3 pharmacokinetic assessments and 46 (92%) completed all 6

88 tic assessments and 46 (92%) completed all 6 pharmacokinetic assessments.

89 We aimed to determine apixaban pharmacokinetics at steady state in patients on hemodial

90 Poor circulation stability causes loss of pharmacokinetics benefits of nanoparticles.

91 a mouse model, exhibit a modest increase in pharmacokinetic bioavailability.

92 -positive EGA; here, we evaluate the safety, pharmacokinetics, biodistribution, and dosimetry (89)Zr-

93 In this study, we evaluated the pharmacokinetics, biodistribution, and dosimetry of pemb

94 od drawing were performed over 8 d to assess pharmacokinetics, biodistribution, and dosimetry.

95 ts, and blood draws were performed to assess pharmacokinetics, biodistribution, and dosimetry.

96 To evaluate the single-dose pharmacokinetic bioequivalence of 3 (1 branded and 2 gen

97 There was no interference to gemcitabine pharmacokinetics by IVC administration.

98 higher stability and potency with prolonged pharmacokinetics could be compatible with very infrequen

99 e with Alzheimer's disease by combining: (i) pharmacokinetic data (280 venous samples) from a phase I

100 Pharmacokinetic data for 16 was generated in mouse with

101 alence data in healthy volunteers because no pharmacokinetic data in recipients were available for al

102 Pharmacokinetic data suggest that 800 mg administered ev

103 These human pharmacodynamic and pharmacokinetic data, although limited to 3 subjects, of

104 human Src inhibition, hERG activity, in vivo pharmacokinetic data, and efficacy in other mouse models

105 nizable function that might compromise their pharmacokinetic distribution and behavior.

106 ghts the fact that quantitative knowledge of pharmacokinetic, drug interaction, and evolutionary proc

107 331007 in adolescents were within predefined pharmacokinetic equivalence boundaries of 50%-200%.

108 The present study considered the pharmacokinetic evaluation of empagliflozin after admini

109 f dosing, 10 patients underwent an intensive pharmacokinetic evaluation of the concentrations of sofo

110 t only provided the quantitative results for pharmacokinetic evaluation, but also revealed valuable i

111 A pharmacokinetics evaluation of the therapeutic Ab reveal

112 All patients underwent sequential pharmacokinetic evaluations of their prestudy FIX and rF

113 In vitro pharmacokinetic experiments show that compound 3 is high

114 A from thermal paper receipts occurs but BPA pharmacokinetics following dermal exposure is not unders

115 based tracer (99m)Tc-RYM1 displays favorable pharmacokinetics for early vascular imaging and enables

116 compounds, including D1 agonists with better pharmacokinetics, functionally selective D1 ligands, and

117 The Phase-1 evaluation of safety and pharmacokinetics has been completed, allowing for the in

118 hat [(18)F]BF4(-) was superior due to better pharmacokinetics, i.e. faster tumor uptake and faster an

119 transferase (AT) inhibitor, shows comparable pharmacokinetics, improved safety and tolerability, and

120 drimer size on brain uptake and explored the pharmacokinetics in a clinically-relevant canine model o

121 We explored the pharmacodynamics and pharmacokinetics in a rabbit model.

122 y-phase trials that assess dose, safety, and pharmacokinetics in a variety of tumor types and later p

123 subset of the inhibitors as well as in vivo pharmacokinetics in mice for a candidate with promising

124 Pharmacokinetics in mice suggested the Cmax to be 12.0 +

125 excellent microsomal stability and good oral pharmacokinetics in rats and mice.

126 the identification of 7 which had good oral pharmacokinetics in rats and showed efficacy in a rat ch

127 s spectrometry (ICP-MS) to examine cisplatin pharmacokinetics in the cochleae of mice and humans.

128 guided by high-resolution, patient-specific pharmacokinetics (including feedback-controlled drug del

129 Finally, a general review of possible pharmacokinetic interactions is included to assist the H

130 ns for the mechanism of action, taking Doxil pharmacokinetics into account.

131 Finally, pharmacokinetic investigations of a divalent GLP-1 analo

132 therapy while simultaneously skirting their pharmacokinetic limitations.

133 function may require consideration of these pharmacokinetic limitations.

134 erivatives while exhibiting greatly improved pharmacokinetics, low projected cost of goods, prophylac

135 s, a human liver cell line commonly used for pharmacokinetic, metabolism and genomic studies, culture

136 ntrast enhanced MRI (DCE-MRI) coupled with a pharmacokinetic model can detect and quantify changes in

137 A pharmacokinetic model of intake and disposition of the c

138 or each region of interest and each subject, pharmacokinetic modeling allowed calculation of the nond

139 egistered with each other and analyzed using pharmacokinetic modeling software.

140 1)C-erlotinib brain uptake was quantified by pharmacokinetic modeling using volume of distribution (V

141 Voxelwise pharmacokinetic modeling was conducted using an irrevers

142 By use of physiologically-based pharmacokinetic modeling, in vitro toxicity data were fi

143 or to typical serum concentrations requires pharmacokinetic modeling.

144 Different pharmacokinetic models were applied to quantify ERbeta a

145 Two compartmental pharmacokinetic models were tested: the 2-tissue model a

146 We aimed to show the pharmacokinetic non-inferiority of subcutaneous rituxima

147 mixed effects modelling was used to describe pharmacokinetic-occupancy curves in caudate, putamen and

148 and rats showed similar biodistribution and pharmacokinetics of (89)Zr-Df-pembrolizumab.

149 The pharmacokinetics of (99m)Tc-PSMA-I&S in humans were inve

150 valuate the biodistribution, metabolism, and pharmacokinetics of a new type I collagen-targeted magne

151 idine dehydrogenase (DPYD) and its effect on pharmacokinetics of and response to 5-fluorouracil (5-FU

152 ion study assessed the safety, efficacy, and pharmacokinetics of anti-CD38 monoclonal antibody isatux

153 es provide precision tools for analyzing the pharmacokinetics of antibodies in an immune response and

154 We aimed to establish the safety and pharmacokinetics of avelumab in patients with solid tumo

155 To compare the pharmacokinetics of dermal and dietary BPA exposure, six

156 e investigated the safety, tolerability, and pharmacokinetics of DSM265, and tested its antimalarial

157 endpoints were the safety, tolerability, and pharmacokinetics of gilteritinib.

158 it plays important roles in determining the pharmacokinetics of many drugs.

159 In a porcine model, pharmacokinetics of PGZ from fat depots transplanted per

160 3 study assessing the safety, efficacy, and pharmacokinetics of recombinant factor IX Fc fusion prot

161 We aimed to assess the efficacy, safety, and pharmacokinetics of rilotumumab combined with epirubicin

162 The pharmacokinetics of sofosbuvir and its metabolite GS-331

163 Reliable methods to define dose and pharmacokinetics of T cell therapies need to be develope

164 However, the pharmacokinetics of the Alexa750-labeled antibody format

165 has distinct advantages: it can improve the pharmacokinetics of the drug, enhance efficacy, and redu

166 g approach that maintains the native in vivo pharmacokinetics of the nanoparticles.

167 indicating that the size could affect ocular pharmacokinetics of the nanoparticles.

168 In vivo tumor targeting and pharmacokinetics of the radiotracers were also evaluated

169 (hAOX), for applications in drug design and pharmacokinetic optimization.

170 ity nor clinical efficacy was reported, only pharmacokinetic or pharmacodynamic outcomes were reporte

171 oid withdrawal scales, and physiological and pharmacokinetic outcomes.

172 ortional manner; isatuximab and lenalidomide pharmacokinetic parameters appeared independent.

173 The insignificant difference in pharmacokinetic parameters between Egyptians and white G

174 The main pharmacokinetic parameters estimated were Cmax, Tmax, t1

175 The pharmacokinetic parameters of breast cancer were calcula

176 y-4-cholesten-3-one (C4), and changes in the pharmacokinetic parameters of ursodeoxycholic acid and i

177 n describe doxorubicin pharmacokinetics, and pharmacokinetic parameters vary significantly among the

178 Pharmacokinetic parameters were calculated after measure

179 datasets were reconstructed, and parametric pharmacokinetic parameters were compared between the 2 r

180 Whole-tumor-averaged parametric pharmacokinetic parameters were compared with those obta

181 In an in vivo study in mice, lycopene pharmacokinetic parameters were improved by lycopene/OEG

182 ods A patient-specific physiologically based pharmacokinetic (PBPK) model of the human cardiovascular

183 Physiologically based pharmacokinetic (PBPK) modeling is a powerful in silico

184 ng iterative Bayesian network modeling and a pharmacokinetic-pharmacodynamic model.

185 Using pharmacokinetic-pharmacodynamic modelling and mouse-huma

186 tial metabolic processing events and defines pharmacokinetic-pharmacodynamic relationships.

187 Pharmacokinetic/pharmacodynamic (PK/PD) analysis in pati

188 We therefore assessed whether pharmacokinetic/pharmacodynamic (PK/PD) parameters could

189 In this study, we developed a pharmacokinetic/pharmacodynamic mathematical model that

190 l/modeling approach to establish an in vitro pharmacokinetic/pharmacodynamic model to describe how th

191 ey are based on a combination of MIC values, pharmacokinetic/pharmacodynamic values, and clinical out

192 se II dose (RP2D), and the schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activi

193 human study were to characterize the safety, pharmacokinetics, pharmacodynamics, and efficacy, and to

194 olving gram-positive pathogens include (1) a pharmacokinetics/pharmacodynamics study to evaluate the

195 chanism of synergy and optimizing antibiotic pharmacokinetics/pharmacodynamics.

196 here is a lack of knowledge as to which drug pharmacokinetic (PK) characteristics are key to generate

197 ugh commonly used in avian medicine, limited pharmacokinetic (PK) data in domestic and companion bird

198 NNRTIs) are hindered by their unsatisfactory pharmacokinetic (PK) properties along with the rapid dev

199 Extensive biophysical analyses and pharmacokinetic (PK) studies in mouse, rat, and monkey f

200 g renal transplant recipients has increased, pharmacokinetic (PK) studies of immunosuppressants rarel

201 r organ-specific processing: terfenadine for pharmacokinetics (PK) and toxicity; trimethylamine (TMA)

202 The pharmacokinetics (PK) studies of immunosuppressive drugs

203 The cellular uptake mechanisms, pharmacokinetics (PK), administration routes and major c

204 proliferation assays and in vivo using mouse pharmacokinetics (PK).

205 We assessed the pharmacodynamics, pharmacokinetics, preliminary efficacy, and safety of BP

206 Further improvement of potency and pharmacokinetics produced in vivo proof-of-concept tool

207 to 1F11, which presented a dose-proportional pharmacokinetic profile and a half-life of 12 days.

208 Secondary outcomes were to assess the pharmacokinetic profile and analyse efficacy, including

209 y of a given injected dose by improving both pharmacokinetic profile and bioavailability of the HP-be

210 I3Kbeta/delta inhibitor displaying excellent pharmacokinetic profile and efficacy in a human PTEN-def

211 in preclinical species) and has a predicted pharmacokinetic profile of a high peak to trough ratio a

212 so evaluated in vivo, revealing a profitable pharmacokinetic profile of the prodrug associated with a

213 g toxicities (DLTs), maximum tolerated dose, pharmacokinetic profile, and response rates.

214 g tau PET tracer candidate, with a favorable pharmacokinetic profile, as compared with (18)F-AV1451.

215 erated in adolescents and had an appropriate pharmacokinetic profile.

216 wn to cause undesirable effects and has poor pharmacokinetic profile.

217 prodrug (29) with an improved solubility and pharmacokinetic profile.

218 ctive inhibitors that demonstrated favorable pharmacokinetic profiles and were devoid of the aforemen

219 s of CTLA4-Ig fusion molecules with enhanced pharmacokinetic profiles could yield improved therapies

220 ity of E-AB sensors to measure complete drug pharmacokinetic profiles in live rats with precision of

221 Differences in the tumour pharmacokinetic profiles of EP-3533 and EP-3612 were uti

222 he tailoring of formulations to impart novel pharmacokinetic profiles once delivered into tissue.

223 RA formulation, consistent with its improved pharmacokinetic profiles.

224 release rate of the drug to generate diverse pharmacokinetic profiles.

225 entration changes as well as long-time scale pharmacokinetic profiles.

226 antagonists have unusual pharmacodynamic and pharmacokinetic properties (slow development of KOP-r se

227 These new ligands have favorable pharmacokinetic properties and effectively suppressed gr

228 es to improve otoprotective potency, improve pharmacokinetic properties and eliminate off-target acti

229 However, 42 showed only moderate pharmacokinetic properties and limited oral bioavalabili

230 aluated in vitro and in vivo regarding their pharmacokinetic properties and metabolic stability.

231 ir selectivity, molecular mode of action and pharmacokinetic properties have been poorly characterize

232 ully realised once their physicochemical and pharmacokinetic properties have been precisely controlle

233 med both at increasing potency and improving pharmacokinetic properties led to the discovery of the c

234 Three major areas of concern are that the pharmacokinetic properties of generic products and the i

235 The improved pharmacokinetic properties of siRNA-L2 facilitated signi

236 ly affect the inherent effector functions or pharmacokinetic properties of the corresponding subclass

237 gment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administrat

238 lted endowed with better physicochemical and pharmacokinetic properties than the parent compound.

239 ity to GPIIb/IIIa receptors and has suitable pharmacokinetic properties to overcome limitations of pr

240 s of peptide drugs, in particular their poor pharmacokinetic properties, and how these efforts have b

241 ivity of anthocyanins is influenced by their pharmacokinetic properties, but anthocyanins are associa

242 profile leading to favorable predicted human pharmacokinetic properties, including a predicted half-l

243 After optimization of metabolic and pharmacokinetic properties, including PXR activation, CY

244 YP3A4 time-dependent inhibition, and improve pharmacokinetic properties, led to the identification of

245 trometry (MS) for the determination of their pharmacokinetic properties, particularly their catabolis

246 is hampered by siRNA's comprehensively poor pharmacokinetic properties, which necessitate molecule m

247 nhibitor scaffolds to improve solubility and pharmacokinetic properties.

248 tides due to their inherently more favorable pharmacokinetic properties.

249 n humans, due to associated toxicity or poor pharmacokinetic properties.

250 etabolic half-lives in HLMs and good in vivo pharmacokinetic properties.

251 issues regarding production, stability, and pharmacokinetic properties.

252 D-1 inhibitors with good physicochemical and pharmacokinetic properties.

253 ted apoE pathway, with improved efficacy and pharmacokinetic properties.

254 ve PDE2a enzyme inhibitor with favorable rat pharmacokinetic properties.

255 A2AAdoR) antagonist with reasonable ADME and pharmacokinetic properties.

256 ticular, exhibited optimal in vitro ADME and pharmacokinetics properties and dose-dependently counter

257 mes as the reference standard and to compare pharmacokinetic rate constants of (18)F-FDG metabolism,

258 Herein, we report a comprehensive structure: pharmacokinetic relationship study of a library of 25 no

259 on-targeted aerosol method produced nicotine pharmacokinetics resembling cigarette smoking in humans.

260 Analyses of SNA biodistribution and pharmacokinetics revealed rapid intratumoral uptake and

261 Pharmacokinetic, safety, and virology endpoints were als

262 In this study, we aimed to assess the pharmacokinetics, safety, and efficacy of this regimen i

263 ysis included a subset of patients with rich pharmacokinetic samples from two selected disease-specif

264 Intensive 24-hour pharmacokinetic sampling was performed in the third trim

265 The pharmacokinetics shows that both intravenous and subcuta

266 GranSim reproduces in vivo plasma pharmacokinetics, spatial and temporal tissue pharmacoki

267 Biodistribution, pharmacokinetics, SPECT/CT, and dosimetry studies were p

268 oups are necessary to compare results across pharmacokinetic studies and to assess potential subgroup

269 During the 8-week study period, pharmacokinetic studies assessed the bioequivalence of G

270 d showcase the racemization of the scaffold, pharmacokinetic studies in preclinical species, and the

271 Pharmacokinetic studies in rats demonstrated 3.3-fold hi

272 The pharmacokinetic studies of the optimized formulation wer

273 METHODS AND Published pharmacokinetic studies on piperaquine were identified t

274 Pharmacokinetic studies revealed that compound 57 had a

275 Our pharmacokinetic studies revealed that intravenously admi

276 on efficiency was further confirmed from the pharmacokinetic studies since the nanoporous mannitol ex

277 These results along with pharmacokinetic studies suggest that 6j could be a promi

278 In vivo pharmacokinetic studies were carried out on hairless rat

279 Additionally, in vivo pharmacokinetic studies were implemented and the PRP's a

280 g microfluidic devices for advanced cell and pharmacokinetic studies.

281 In the ILLUMENATE PK study (Pharmacokinetic Study of the Stellarex Drug-Coated Angio

282 Pharmacokinetic study revealed that DC nanozymes signifi

283 d was applied successfully on the underlying pharmacokinetic study with enhanced sample preparation t

284 gh concentrations of exposure in plasma by a pharmacokinetic study, and (3) reduce the tumor size of

285 ized, one treatment, one period, single dose pharmacokinetic study.

286 Based on pharmacokinetics, target occupancy, and immunological an

287 Pretransplant pharmacokinetic testing was performed to determine the m

288 jection site reaction (ISR) grading), plasma pharmacokinetic (time-to-minimum-effective-concentration

289 on, South Korea) has equivalent efficacy and pharmacokinetics to rituximab.

290 We employed an integrated strategy combining pharmacokinetics, toxicology, metabonomics, genomics, an

291 for imaging studies or for assessing plasma pharmacokinetics using equipment that has a highly sensi

292 vailable to enable derivation of one or more pharmacokinetic variables.

293 Equivalence of pharmacokinetics was shown if the 90% CIs for the geomet

294 Pharmacokinetics were assessed in a subset of the safety

295 Piperaquine pharmacokinetics were described successfully by a three-

296 Veliparib pharmacokinetics were dose proportional, with no effect

297 Plasma pharmacokinetics were modeled with a biexponential funct

298 The tumor uptake, biodistribution, and pharmacokinetics were not significantly different from t

299 ition, this technique characterized cellular pharmacokinetics with heterogeneous delivery after 1 day

300 macology models that integrated cellular PTX pharmacokinetics with PTX pharmacodynamics successfully

301 ld potentially be developed to achieve novel pharmacokinetics, without consideration of that particul